护肝宁片治疗非酒精性脂肪性肝炎的实验研究  

Effect of Huganning tablet on nonalcoholic steatohepatifis in rats

作　　者：万华[1] 杨国生[1] 陶迎红[1] 席宏丽[1] 王学晶[1] 徐小元[1] 

机构地区：[1]北京大学第一医院感染疾病科,100034

出　　处：《中国医药》2010年第8期717-719,共3页China Medicine

摘　　要：目的探讨护肝宁片对大鼠非酒精性脂肪性肝炎的治疗作用及机制。方法雄性SD大鼠39只，正常喂养1周后按体质量层次随机分为正常对照组（n=9）和实验组（n=30），正常对照组予标准饮食，实验组予高脂饮食。11周末验证造模成功后，将余下25只实验组大鼠再分为：高脂组、饮食治疗组，及护肝宁高剂量组、中剂量组、低剂量组。分别给予高剂量、中剂量、低剂量护肝宁片灌胃及标准饮食。16周末处死大鼠，检测肝指数、体脂比、血清ALT、AST、TC、TG、LDL．C、血糖、超氧化物歧化酶（SOD）、丙二醛，并行肝组织病理检查及肝匀浆TC，TG，LDL—C和丙二醛测定。结果护肝宁中剂量组、护肝宁低剂量组体脂比[分别为（3．08±0．49）％与（3．07±0．82）％]较饮食治疗组及高脂组降低（P〈0．05）；护肝宁高剂量组血清AST水平、TC水平、血糖水平及肝匀浆11c水平[分别为（119．8±14．7）U／L、（1．59±0．38）mmo]／L、（5．44±0．44）mmol／L及（0．34±0．07）mmol／L]明显低于饮食治疗组，护肝宁高剂量组血清SOD水平[（47．38±5．72）％]明显高于饮食治疗组（P〈0．05）；护肝宁高剂量组较饮食治疗组及高脂组肝组织的脂肪变程度、炎症程度和纤维化程度均明显减轻（P〈0．05）。结论护肝宁片可有效治疗大鼠非酒精性脂肪性肝炎。Objective To investigate the protective effect and mechanism of Huganning tablet on rat model of nonalcoholic steatohepatitis （NASH）. Methods After one week of a standard diet 39 male SD rats were randomly divided into the normal control group（ n = 9） and the experimental group （n = 30）. The normal control group rats were fed with a standard diet, while those of the experimental group had a high-fat diet. After 10 weeks 9 rats were sacrificed to verify whether the model was established successfully. Then the experimental group was randomly subdivided into five groups：Group Z（n=5） with a high-fat diet and gastric with saline, Group Y（n =5） with a standard diet and gastric with saline, Group A （ n = 5 ）, Group B （ n = 5） and Group C （ n = 5 ） with a standard diet and gastrically infused with the Huganning Tablet solution of high-dosage （700 mg/kg/d）, middle-dosage （350 mg/kg/ d） and low-dosage（ 175 mg/kg/d）, respectively. Four weeks later, all rats were sacrificed. Blood samples were collected to measure serum ALT, AST, TG, TC, LDL-C, GLU, SOD and MDA. Tissue samples were duly taken for histopathological examination and measurement of tissue TC, TG, LDL-C and MDA levels. Results There were lower levels of visceral adiposity ratio in Group B and Group C compared with Group Y（ P 〈 0.05 ）. There were lower levels of serum AST, TC, GLU and liver tissue TC in Group A compared to Group Y（P 〈0.05）. A significant increase was found in the serum SOD levels in Group A compared to Group Y （P 〈 0.05）. A significant reduction was observed in Group A in the hepatic steatosis, the grade of inflammation and the stage of fibrosis compared to Group Y and Group Z （P 〈 0.05）. Conclusions Huganning Tablet seems to be effective in attenuating hepatic damage in the NASH model induced by a high-fat diet, which may become a potential drug for NASH treatment in the future.

关 键 词：肝炎 大鼠 护肝宁片 

分 类 号：R575.1[医药卫生—消化系统]